Objectives
This paper aims to address the concerns around ongoing immune activation, inflammation, and resistance in those ageing with HIV that represent current challenges for clinicians.
Methods
Presentations at a symposium addressing issues of ageing with HIV infection were reviewed and synthesised.
Results
The changing natural history and demographics of human immunodeficiency virus (HIV)âinfected individuals means new challenges in contemporary management. In the early years of the epidemic,management was focussed on acute, potentially lifeâthreatening AIDSârelated complications. From initial monotherapy with firstâgeneration antiretroviral therapy (ART), the development of combination highly active ART (HAART) allowed HIV control but ART toxicities, treatment adherence and drug resistance emerged as major issues. Today, the availability of potent and tolerable ART has made viral suppression achievable in most people living with HIV (PLHIV), and clinicians are confronted with managing a chronic condition among an ageing population. The combination of diseases of ageing and the coâmorbidities associated with HIVâinfection, even when well controlled, results in a complex set of challenges for many older PLHIV. There is a growing appreciation that many nonâAIDSârelated coâmorbidities are caused, at least in part, by persistent, lowâgrade immune activation, inflammation, and hypercoagulability, despite suppressive ART.
Conclusions
In order to further improve HIV management, it is important to understand the enduring effects of chronically suppressed HIV infection, the potential contribution of these factors to the ageing process, the possibility of drug resistance, and the impact of different treatment strategies, including early ART initiation.